IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma (NCT07185490) | Clinical Trial Compass
Not Yet RecruitingEarly Phase 1
IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
40 participantsStarted 2026-02-15
Plain-language summary
This study is a single-center, open-label, dose-exploration trial designed to evaluate the tolerability and safety of different doses of IASO104 in patients with relapsed/refractory plasma cell neoplasms, determine the recommended dose of IASO104, and assess its pharmacokinetic and pharmacodynamic characteristics. Additionally, the study will preliminarily observe the efficacy of the investigational drug in a small sample of subjects with relapsed/refractory multiple myeloma.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age 18-75 years, any gender.
. Diagnosis of multiple myeloma (MM) per International Myeloma Working Group (IMWG) diagnostic criteria.
. Prior therapy requirements:
. Documented disease progression during/within 12 months after last anti-myeloma therapy (exemption: No 12-month requirement if last line was CAR-T).
. Measurable disease at screening (≥1 of the following):
. ECOG performance status 0-1.
. Life expectancy ≥12 weeks.
. Adequate organ function (all lab values within 7 days prior to enrollment):
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is an early Phase 1 trial for IASO104 that hasn't started recruiting yet, and the main thing being measured is how often and how severely side effects occur, what does that mean for what's actually known right now about whether this drug is safe or effective for my situation?
2Given that my diagnosis is relapsed or refractory multiple myeloma, are there currently approved treatments or other trials in later phases that my care team would recommend I try before considering a Phase 1 study like this one?
3Because this trial isn't recruiting yet, how would we know when it opens, and is it worth staying in contact with the research team now so we're prepared if I become eligible later?
4What would make someone with relapsed or refractory multiple myeloma — or plasma cell leukemia — a good or poor candidate for a trial like this, and how does my current disease status and treatment history fit that picture?
5If I were to eventually enroll in a Phase 1 trial focused on finding a safe dose and tracking adverse events, what kinds of side effects should I be prepared to discuss, and how would my care be managed if serious ones occurred?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
incidence and severity of adverse events (AEs)
Timeframe: Minimum 2 years after IASO104 infusion
Trial details
NCT IDNCT07185490
SponsorInstitute of Hematology & Blood Diseases Hospital, China